Individualized medicine in the treatment of human prostate cancer using laser-captured microdissection technique
Project/Area Number |
24592377
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | The University of Tokyo |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
YUKIO Homma 東京大学, 医学部附属病院, 教授 (40165626)
SATOSHI Inoue 東京大学, 医学部附属病院, 特任教授 (40251251)
浦野 友彦 東京大学, 医学部附属病院, 講師 (20334386)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 前立腺癌 / 内分泌療法 / アンドロゲン / エストロゲン / 幹細胞 / 分子診断 / アンドロゲン受容体 / エストロゲン受容体 / レーザーマイクロダイセクション / 予後 |
Outline of Final Research Achievements |
We developed models to predict CF using biopsy samples from a training set of 46 and independent validation set of 30 patients with treatment-naïve PC with bone metastasis. Cancerous and stromal tissues were separately collected by laser-captured microdissection.Logistic analyses to predict PSA recurrence showed an area under the curve (AUC) of 1.0 in both sets for Sox2, Her2, and CRP expression in cancer cells; AR and ERα expression in stromal cells; and clinical parameters. We identified 10 prognostic factors for cancer-specific survival (CSS): Oct1, TRIM36, Sox2, and c-Myc expression in cancer cells; AR, Klf4, and ERα expression in stromal cells; and PSA, Gleason score, and extent of disease. On the basis of these factors, patients were divided into favorable-, intermediate-, and poor-risk groups according to the number of factors present. Five-year CSS rates for the 3 groups were 90%, 32%, and 12% in training set and 75%, 48%, and 0% in validation set, respectively.
|
Report
(4 results)
Research Products
(5 results)
-
[Journal Article] Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer2014
Author(s)
Fujimura T, Takahashi S, Urano T, Takayama K, Sugihara T, Obinata D, Yamada Y, Kumagai J, Kume H, Ouchi Y, Inoue S, Homma Y
-
Journal Title
Clin Cancer Res
Volume: 20
Issue: 17
Pages: 4625-4635
DOI
Related Report
Peer Reviewed
-
[Presentation] Expression of androgen and estrogen signalling components and stem cell markers is highly predictive cancer progression of metastatic prostate cancer2014
Author(s)
Fujimura T, Takahashi S, Urano T, Kume H, Takayama K, Murata T, Yamada Y, Obinata D, Inoue S, Homma Y.
Organizer
29th Annual EAU Congress
Place of Presentation
Stockholm, Sweden
Related Report
-
[Presentation] Expression of androgen and estrogen signaling components and stem cell markers predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer2014
Author(s)
Fujimura T, Takahashi S, Urano T, Kume H, Takayama K, Murata T, Yamada Y, Obinata D, Inoue S, Homma Y
Organizer
AUA Annual Meeting
Place of Presentation
Florida, USA
Related Report
-
[Presentation] Expression of androgen and estrogen signaling and stem cell markers predicts cancer progression and cancer specific survival.2013
Author(s)
Fujimura T, Takahashi S, Urano T, Kume H, Takayama K, Murata T, Yamada Y, Obinata D, Inoue S, Homma Y.
Organizer
33nd SIU Congress
Place of Presentation
Vancouver, Canada.
Related Report
-